Tissue Regenix potential acquisition target as tech nears clinic
This article was originally published in Clinica
Executive Summary
UK regenerative medicine firm Tissue Regenix could soon become an acquisition target with a price tag of up to $350m, according to Panmure Gordon analyst Savvas Neophytou. But any potential deal is contingent upon the firm’s technology platform, dCELL, being successfully commercialized, he added.